You are here

  • Home
  • Archive
  • Volume 10, Issue 10
  • Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

https://doi.org/10.1136/jitc-2021-004022corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Xiao M, Xie L, Cao G, et al. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. J Immunother Cancer 2022;10:e004022. doi: 10.1136/jitc-2021-004022

    The funding statement has been updated to:

    This study was supported by grants from the National Key Research and Development Program of China (NO. 2021YFC-2300602 to LY) and the National Natural Science Foundation of China (No. 32030041 to LY, No. 81702443 to SL).